Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 18, 2005
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
R Mukhtar, J P D Reckless
Expert Opinion on Pharmacotherapy
|
November 20, 2002
Fluvastatin
J M Lawrence, J P D Reckless
International Journal of Clinical Practice
|
April 28, 2005
Pitavastatin
R Y A Mukhtar, J Reid, J P D Reckless
International Journal of Clinical Practice
|
June 4, 2010
Counterweight - counter-cost, counter-loss
M E J Lean, J P D Reckless, N Finer, et al.
Atherosclerosis
|
May 12, 2004
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
J M Lawrence, J Reid, G J Taylor, et al.
Pharmacoeconomics
|
March 21, 2013
Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal
E L Simpson, P Fitzgerald, P Evans, et al.
International Journal of Clinical Practice
|
February 13, 2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
J P D Reckless, P Henry, T Pomykaj, et al.
European Journal of Clinical Nutrition
|
July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight Programme
M McQuigg, J Brown, J Broom, et al.
Obesity Research & Clinical Practice
|
December 20, 2013
The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change
M McQuigg, J E Brown, J Broom, et al.
International Journal of Clinical Practice
|
April 1, 2010
Long-term cost-effectiveness of weight management in primary care
P Trueman, S M Haynes, G Felicity Lyons, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 18, 2005
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
R Mukhtar, J P D Reckless
Expert Opinion on Pharmacotherapy
|
November 20, 2002
Fluvastatin
J M Lawrence, J P D Reckless
International Journal of Clinical Practice
|
April 28, 2005
Pitavastatin
R Y A Mukhtar, J Reid, J P D Reckless
International Journal of Clinical Practice
|
June 4, 2010
Counterweight - counter-cost, counter-loss
M E J Lean, J P D Reckless, N Finer, et al.
Atherosclerosis
|
May 12, 2004
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
J M Lawrence, J Reid, G J Taylor, et al.
Pharmacoeconomics
|
March 21, 2013
Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal
E L Simpson, P Fitzgerald, P Evans, et al.
International Journal of Clinical Practice
|
February 13, 2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
J P D Reckless, P Henry, T Pomykaj, et al.
European Journal of Clinical Nutrition
|
July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight Programme
M McQuigg, J Brown, J Broom, et al.
Obesity Research & Clinical Practice
|
December 20, 2013
The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change
M McQuigg, J E Brown, J Broom, et al.
International Journal of Clinical Practice
|
April 1, 2010
Long-term cost-effectiveness of weight management in primary care
P Trueman, S M Haynes, G Felicity Lyons, et al.
Page
of 1